AI Article Synopsis
- - Suvorexant (Belsomra®) is a new insomnia medication available since 2014 that works as a dual orexin receptor antagonist, helping people sleep by blocking certain receptors in the brain.
- - The report details the identification and measurement of suvorexant in three autopsy cases using advanced lab techniques like gas chromatography/mass spectrometry and liquid chromatography-tandem mass spectroscopy.
- - This study marks the first time suvorexant has been quantified in postmortem specimens, suggesting that it may be increasingly relevant in forensic toxicology in the future.
Article Abstract
Suvorexant (Belsomra®) is a relatively new insomnia medication that has been available in USA and Japan since 2014. It is a dual orexin receptor antagonist that promotes sleep by inhibiting the binding of orexin neurons to the OX1R and OX2R receptors. In this report, we describe the detection and quantitation of suvorexant from the postmortem specimens of three separate autopsy cases handled by our department. Suvorexant was identified by fast gas chromatography/mass spectrometry during routine screening, and quantitated by a fully validated liquid chromatography-tandem mass spectroscopy method. Quantitation was achieved by positive electrospray ionization in the selected reaction monitoring mode. Monitored transitions were m/z 451 > 186 for quantitation and m/z 451 > 104 for qualification. To our knowledge, this is the first instance of suvorexant being quantitated from actual autopsy cases. It is likely that this compound will be encountered more often by the forensic toxicology community going forward.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jat/bkx110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!